

The future of the life sciences sector in the UK - funding, regulation and the impact of Brexit

1st March 2017

CONDITIONS FOR USE OF TRANSCRIPTS:

This document is intended to provide a timely reference for interested parties who are unable to attend the event to which it refers. Some portions are based on transcripts of proceedings and others consist of text submitted by speakers or authors, and are clearly marked as such. As such, apart from where it is indicated that the text was supplied by the speaker, it has not been possible for the transcript to be checked by speakers and so this portion of the document does not represent a formal record of proceedings. Despite best endeavours by Westminster Forum Projects and its suppliers to ensure accuracy, text based on transcription may contain errors which could alter the intended meaning of any portion of the reported content. Anyone who intends to publicly use or refer to any text based on the transcript should make clear that speakers have not had the opportunity for any corrections, or check first with the speaker in question. If in doubt, please contact the forum first.

Contents

<u>About this Publication</u>	3
<u>Agenda</u>	4
<u>Session Chair's opening remarks</u>	
Daniel Zeichner MP, Vice Chair, All-Party Parliamentary Group for Life Sciences (<i>transcript</i>)	6
<u>Assessing the challenge of Brexit for the life sciences sector</u>	
Professor Sir Robert Lechler, President, The Academy of Medical Sciences and Executive Director, King's Health Partners (<i>transcript</i>)	8
Questions and comments from the floor (<i>transcript</i>)	12
<u>Priorities for the UK EU Life Sciences Transition Programme</u>	
<u>Funding, access and supporting innovation</u>	
Dr Rebecca Lumsden, Head of Science Policy, ABPI (<i>transcript</i>)	15
<u>Supporting the development of medical technologies</u>	
Nishan Sunthares, Chief Operating Officer, ABHI (<i>transcript</i>)	18
<u>Key issues for the regulation and adoption of diagnostics</u>	
Doris-Ann Williams, Chief Executive, British In Vitro Diagnostics Association (<i>transcript</i>)	20
<u>Challenges for medical research, encouraging collaboration and engagement from the third sector</u>	
Aisling Burnand, Chief Executive, Association of Medical Research Charities (<i>transcript</i>)	23
<u>Developing the workforce: skills, recruitment and retention</u>	
Joanna Woolf, Chief Executive, Cogent Skills (<i>transcript</i>)	26
Questions and comments from the floor (<i>transcript</i>)	29
<u>Session Chair's closing remarks</u>	
Daniel Zeichner MP, Vice Chair, All-Party Parliamentary Group for Life Sciences (<i>transcript</i>)	38
<u>Session Chair's opening remarks</u>	
Mariana Dates, Principal Consultant, Optimity Advisors (<i>transcript</i>)	39
<u>'Creating new hubs for life sciences - making the most of regional opportunities'</u>	
Dr John Williams, Managing Director, Birmingham Health Partners (<i>transcript</i>)	40
<u>The future of regulation, international engagement and the evolving role of the MHRA</u>	
Dr Ian Hudson, Chief Executive, MHRA and Member (UK), Management Board, European Medicines Agency (<i>transcript</i>)	42
<u>Key issues for access to medicines and the NICE appraisal process</u>	
Professor Carole Longson, Director, Centre for Health Technology Evaluation, NICE (<i>transcript</i>)	48
Questions and comments from the floor (<i>transcript</i>)	53
<u>Session Chair's and Westminster Health Forum closing remarks</u>	
Mariana Dates, Principal Consultant, Optimity Advisors (<i>transcript</i>)	61
Matthew Bradberry, Forum Lead, Westminster Health Forum (<i>transcript</i>)	62
<u>Comments</u>	
Linda Summerton, CEO, Immodulon Therapeutics	63
Edward Draper, Managing Director Ortheia	64
Dr Ewa Truchanowicz, Business Engagement Manager University of Birmingham	65
<u>List of Delegates Registered for Seminar</u>	67
<u>Contributor Biographies</u>	76
<u>About the Core Sponsors of the Westminster Health Forum</u>	78
Please be advised that speakers' PowerPoint presentations are included within the transcript itself, just beneath the relevant speaker's text. Please note that not all speakers are able to grant permission for us to include their slides.	

About this Publication

This publication reflects proceedings at the Westminster Health Forum Keynote Seminar: The future of the life sciences sector in the UK - funding, regulation and the impact of Brexit held on 1st March 2017. The views expressed in the articles are those of the named authors, not those of the Forum or the sponsors, apart from their own articles.

Although Westminster Health Forum is grateful to all sponsors for the funding on which we depend, participation in events and publications is never conditional on being a sponsor. As well as funding ongoing operations, sponsorship enables the Forum to distribute complimentary copies of publications, and offer complimentary tickets for events, to Government ministers, parliamentarians and officials most involved in policy.

This publication is copyright. Its copying, in whole or in part, is not permitted without the prior written consent of the publishers. However, extracts of the text may be reproduced for academic or review purposes, subject to the conditions of use outlined in the previous page, providing they are accurate, are not used in a misleading context and the author, their organisation and the Westminster Health Forum are acknowledged. We would also appreciate being informed.

Westminster Health Forum

UK Headquarters
4 Bracknell Beeches
Old Bracknell Lane West
Bracknell
Berkshire RG12 7BW

T: 01344 864796
F: 01344 420121
publications@westminsterforumprojects.co.uk

Directors

Peter van Gelder
Chris Whitehouse